增殖诱导配体在多发性骨髓瘤中的表达及临床意义  

Expression and clinical significance of a proliferation-inducing ligand in multiple myeloma

作　　者：张桂华[1] 陈令松[1] 张秋荣[1] 徐金格[1] 

机构地区：[1]徐州医学院第二附属医院血液科,江苏徐州226001

出　　处：《中国现代医生》2014年第4期11-13,16,F0003,共5页China Modern Doctor

摘　　要：目的定量分析多发性骨髓瘤患者化疗前后外周血单个核细胞和血浆中增殖诱导配体(APRIL)mRNA及蛋白的表达水平。方法应用酶联免疫吸附试验(ELISA)及实时荧光定量聚合酶链反应(RFQ-PCR)技术测定靶基因及靶蛋白的准确含量。结果 MM患者化疗前APRIL mRNA及蛋白表达水平均显著高于正常对照(P<0.05);化疗前Ⅲ期APRIL mRNA及蛋白表达水平显著高于Ⅰ期及Ⅱ期(P<0.05);化疗后PD组显著高于CR及PR组(P<0.05)。结论 APRIL可能参与MM的发生与发展并与肿瘤负荷量及疗效密切相关,其mRNA与蛋白表达水平相一致,且可能成为有效治疗MM的新靶点。Objective To investigate the expression of a proliferation-inducing ligand （APRIL） in peripheral blood mononuclear cell and plasma of patients with multiple myeloma （MM） before chemotherapy or after chemotherapy. Methods The real-time fluorescence quantitative PCR （RFQ-PCR） was used to detect expression of APRIL mRNA. At the same time, enzyme-linked immune osorbent assay （ELISA） was used to detect expression of APRIL protein. Results The expression levels of APRIL mRNA and protein of patients with MM before chemotherapy were significantly higher than those in control group （P〈0.05）. Before chemical treatment, the expression levels of APRIL mRNA and protein of patients in III stage of MM were significantly higher than those in I or 11 stage （P〈0.05） ;in the treated-patients with MM, the expression levels of APRIL mRNA and protein in PD group were also significantly higher than those of CR and PR groups （P〈0.05）. Conclusion APRIL may be involved in formation and maintenance of MM. Moreover, APRIL may be intimately relative to burden and curative effect of MM. The expression level of APRIL mRNA was parallel to that of APRIL protein. It could be established as target molecule to treat MM efficiently.

关 键 词：增殖诱导配体 多发性骨髓瘤 靶点 酶联免疫吸附试验 

分 类 号：R733.3[医药卫生—肿瘤]